Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics
ALPN Price/Volume Stats
Current price | $39.64 | 52-week high | $42.88 |
Prev. close | $38.65 | 52-week low | $6.71 |
Day low | $37.18 | Volume | 1,462,100 |
Day high | $41.04 | Avg. volume | 1,134,802 |
50-day MA | $31.74 | Dividend yield | N/A |
200-day MA | $17.97 | Market Cap | 2.60B |
ALPN Stock Price Chart Interactive Chart >
ALPN POWR Grades
- Sentiment is the dimension where ALPN ranks best; there it ranks ahead of 87.02% of US stocks.
- The strongest trend for ALPN is in Stability, which has been heading down over the past 26 weeks.
- ALPN's current lowest rank is in the Stability metric (where it is better than 14.24% of US stocks).
ALPN Stock Summary
- Of note is the ratio of ALPINE IMMUNE SCIENCES INC's sales and general administrative expense to its total operating expenses; only 7.85% of US stocks have a lower such ratio.
- With a price/sales ratio of 34.9, ALPINE IMMUNE SCIENCES INC has a higher such ratio than 95.81% of stocks in our set.
- With a year-over-year growth in debt of -34.87%, ALPINE IMMUNE SCIENCES INC's debt growth rate surpasses merely 9.09% of about US stocks.
- Stocks that are quantitatively similar to ALPN, based on their financial statements, market capitalization, and price volatility, are ABUS, IDYA, VIR, STTK, and RNA.
- ALPN's SEC filings can be seen here. And to visit ALPINE IMMUNE SCIENCES INC's official web site, go to www.alpineimmunesciences.com.
ALPN Valuation Summary
- In comparison to the median Healthcare stock, ALPN's EV/EBIT ratio is 233.56% lower, now standing at -19.5.
- ALPN's price/sales ratio has moved NA NA over the prior 104 months.
Below are key valuation metrics over time for ALPN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ALPN | 2023-12-29 | 36.0 | 6.9 | -19.4 | -19.5 |
ALPN | 2023-12-28 | 36.9 | 7.0 | -19.9 | -20.0 |
ALPN | 2023-12-27 | 37.6 | 7.2 | -20.3 | -20.4 |
ALPN | 2023-12-26 | 38.1 | 7.3 | -20.6 | -20.7 |
ALPN | 2023-12-22 | 36.6 | 7.0 | -19.8 | -19.9 |
ALPN | 2023-12-21 | 37.2 | 7.1 | -20.1 | -20.2 |
ALPN Growth Metrics
- The year over year net income to common stockholders growth rate now stands at -42.87%.
- Its 2 year price growth rate is now at 120%.
- Its 5 year net income to common stockholders growth rate is now at -7.57%.
The table below shows ALPN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 31.818 | -41.697 | -54.065 |
2022-06-30 | 31.967 | 4.785 | -54.286 |
2022-03-31 | 33.868 | 6.172 | -47.217 |
2021-12-31 | 23.443 | -15.248 | -50.333 |
2021-09-30 | 24.556 | -9.868 | -41.508 |
2021-06-30 | 17.953 | -45.394 | -34.151 |
ALPN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALPN has a Quality Grade of C, ranking ahead of 68.11% of graded US stocks.
- ALPN's asset turnover comes in at 0.122 -- ranking 247th of 682 Pharmaceutical Products stocks.
- SELB, TXMD, and QGEN are the stocks whose asset turnover ratios are most correlated with ALPN.
The table below shows ALPN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.122 | 1 | -0.458 |
2021-03-31 | 0.086 | 1 | -0.661 |
2020-12-31 | 0.083 | 1 | -0.777 |
2020-09-30 | 0.051 | 1 | -1.140 |
2020-06-30 | 0.044 | 1 | -0.895 |
2020-03-31 | 0.047 | 1 | -0.716 |
ALPN Price Target
For more insight on analysts targets of ALPN, see our ALPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $20.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
Alpine Immune Sciences, Inc. (ALPN) Company Bio
Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.
Latest ALPN News From Around the Web
Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVieSEATTLE, December 21, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept. |
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year. |
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceSEATTLE, December 18, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 7:30 am PT/10:30 am ET, and the Company will participate in one-on-one investor meetings. |
Optimistic Investors Push Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Up 41% But Growth Is LackingDespite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain... |
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey MedicalAurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article. |
ALPN Price Returns
1-mo | 13.52% |
3-mo | 107.97% |
6-mo | 246.20% |
1-year | 428.89% |
3-year | 289.77% |
5-year | 477.84% |
YTD | 107.97% |
2023 | 159.32% |
2022 | -46.93% |
2021 | 9.92% |
2020 | 228.13% |
2019 | 4.35% |
Continue Researching ALPN
Want to do more research on Alpine Immune Sciences Inc's stock and its price? Try the links below:Alpine Immune Sciences Inc (ALPN) Stock Price | Nasdaq
Alpine Immune Sciences Inc (ALPN) Stock Quote, History and News - Yahoo Finance
Alpine Immune Sciences Inc (ALPN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...